Bone Marrow Failure Syndrome Clinical Trial
— ABC-TOPOfficial title:
The Impact of Red Cell Age on Product Utilization in the Chronically Transfused Outpatient Population
Verified date | December 2015 |
Source | University of Calgary |
Contact | n/a |
Is FDA regulated | No |
Health authority | Canada: Ethics Review Committee |
Study type | Interventional |
In this study, the investigators will be evaluating the impact of red blood cell age in
patients receiving chronic blood transfusions in the outpatient setting. This study will
have a double-bind, randomized trial design, meaning that the investigators and participants
will not be told the group assignment at study enrollment.
Study participants will be randomly divided into two groups (50% of participants in each
group) by a computer generated block randomization schema. The 'fresh blood' group will
receive blood units that are 7 or less from the time of donor collection, and the 'aged
blood' group will receive blood units that are greater than 21 to 42 days from the time of
donor collection. The number of units of blood transfused will be decided based on the
participant's hemoglobin level before blood transfusion.
The primary goal of our study is to compare annual red blood cell product use (the number of
units given per patient in a year). The investigators will also be comparing groups to
evaluate the transfusion reaction frequency, iron burden (based on the level of ferritin in
the blood), overall transfusion and care cost difference, and participant time spent in
outpatient departments.
Our hypothesis is that use of fresh blood in chronically transfused patients will lead to a
decrease the in red cell transfusion rate, with subsequent clinical benefits including
reduction of transfusion reaction frequency and systemic iron burden.
This study will be taking place within the Calgary Zone of Alberta Health Services only.
Status | Enrolling by invitation |
Enrollment | 60 |
Est. completion date | December 2017 |
Est. primary completion date | March 2017 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Patients requiring outpatient chronic red cell transfusions (2 or more red blood cell units per month for at least 3 consecutive months) in an ambulatory clinic within the Calgary Zone Exclusion Criteria: - prerequisite for fresh or irradiated blood due to a pre-existing medical reason - hemodialysis dependence - chronic disease that has acutely decompensated, with a life expectancy of less than 3 months |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
University of Calgary |
Hébert PC, Chin-Yee I, Fergusson D, Blajchman M, Martineau R, Clinch J, Olberg B. A pilot trial evaluating the clinical effects of prolonged storage of red cells. Anesth Analg. 2005 May;100(5):1433-8, table of contents. — View Citation
Koch CG, Li L, Sessler DI, Figueroa P, Hoeltge GA, Mihaljevic T, Blackstone EH. Duration of red-cell storage and complications after cardiac surgery. N Engl J Med. 2008 Mar 20;358(12):1229-39. doi: 10.1056/NEJMoa070403. — View Citation
Mynster T, Nielsen HJ. The impact of storage time of transfused blood on postoperative infectious complications in rectal cancer surgery. Danish RANX05 Colorectal Cancer Study Group. Scand J Gastroenterol. 2000 Feb;35(2):212-7. Review. — View Citation
Spinella PC, Carroll CL, Staff I, Gross R, Mc Quay J, Keibel L, Wade CE, Holcomb JB. Duration of red blood cell storage is associated with increased incidence of deep vein thrombosis and in hospital mortality in patients with traumatic injuries. Crit Care. 2009;13(5):R151. doi: 10.1186/cc8050. Epub 2009 Sep 22. — View Citation
Taylor RW, O'Brien J, Trottier SJ, Manganaro L, Cytron M, Lesko MF, Arnzen K, Cappadoro C, Fu M, Plisco MS, Sadaka FG, Veremakis C. Red blood cell transfusions and nosocomial infections in critically ill patients. Crit Care Med. 2006 Sep;34(9):2302-8; quiz 2309. — View Citation
Triulzi DJ, Yazer MH. Clinical studies of the effect of blood storage on patient outcomes. Transfus Apher Sci. 2010 Aug;43(1):95-106. doi: 10.1016/j.transci.2010.05.013. Epub 2010 Jul 24. Review. — View Citation
Weinberg JA, McGwin G Jr, Griffin RL, Huynh VQ, Cherry SA 3rd, Marques MB, Reiff DA, Kerby JD, Rue LW 3rd. Age of transfused blood: an independent predictor of mortality despite universal leukoreduction. J Trauma. 2008 Aug;65(2):279-82; discussion 282-4. doi: 10.1097/TA.0b013e31817c9687. — View Citation
Yürük K, Milstein DM, Bezemer R, Bartels SA, Biemond BJ, Ince C. Transfusion of banked red blood cells and the effects on hemorrheology and microvascular hemodynamics in anemic hematology outpatients. Transfusion. 2013 Jun;53(6):1346-52. doi: 10.1111/j.1537-2995.2012.03905.x. Epub 2012 Sep 24. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Red blood cell transfusion rate | Product utilization, comparing the number and frequency of red blood cell units transfused to the chronically transfused outpatient population eligible for trial participation | 1 year from the time of enrollment | No |
Secondary | Ferritin burden | Based on results of laboratory test results available in the participant's electronic medical record, as ordered as a part of standard care by the primary hematologist | At enrollment, 3 months, 6 months, 9 months and 12 months | No |
Secondary | Total cost of blood product transfusion | Approximate sum of the cost of blood products transfused and nursing services required in the outpatient hospital treatment rooms when transfusions are administered throughout the study period | 1 year from the time of enrollment | No |
Secondary | Number of hours spent receiving blood products | Sum of the number of patient hours spent receiving transfusions in the hospital treatment room setting | 1 year from the time of enrollment | No |
Secondary | Transfusion reaction frequency | Number and type of transfusion reactions experienced by patients receiving transfusions throughout the study period, as reported to transfusion medicine by nursing, according to standard practice protocols | 1 year from the time of enrollment | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT01596699 -
Pilot Trial of Clofarabine Added to Standard Busulfan and Fludarabine for Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation
|
Phase 2 | |
Completed |
NCT00897260 -
Umbilical Cord Blood Transplantation As Treatment Of Adult Patients With Hematologic Disorders
|
N/A | |
Active, not recruiting |
NCT01966367 -
CD34+ (Non-Malignant) Stem Cell Selection for Patients Receiving Allogeneic Stem Cell Transplantation
|
Phase 1/Phase 2 | |
Recruiting |
NCT04819607 -
The Evaluating Multidisciplinary Bone Marrow Failure Care in Bone Marrow Failure and Related Disorders.
|
||
Completed |
NCT03513328 -
Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation
|
Phase 1/Phase 2 | |
Recruiting |
NCT04356469 -
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children
|
Phase 2 | |
Active, not recruiting |
NCT04558736 -
Haploidentical HCT for Severe Aplastic Anemia
|
Phase 2 | |
Recruiting |
NCT01757145 -
Eltrombopag for Enhancing Platelet Engraftment in Adult Patients Undergoing Cord Blood Transplantation
|
Phase 2 | |
Recruiting |
NCT02958462 -
Pre-myeloid Cancer and Bone Marrow Failure Clinic Study
|
N/A | |
Recruiting |
NCT04781790 -
French National Registry of Bone Marrow Failures
|
||
Recruiting |
NCT05236764 -
Haploidentical Hematopoietic Cell Transplantation Using TCR Alpha/Beta and CD19 Depletion
|
N/A | |
Recruiting |
NCT04965597 -
Treosulfan-Based Conditioning Regimen Before a Blood or Bone Marrow Transplant for the Treatment of Bone Marrow Failure Diseases (BMT CTN 1904)
|
Phase 2 | |
Available |
NCT03145545 -
Expanded Access Protocol Using Alpha/Beta T and CD19+ Depleted PBSC
|